Literature DB >> 9542901

Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels.

M Beld1, M Penning, M McMorrow, J Gorgels, A van den Hoek, J Goudsmit.   

Abstract

Hepatitis C virus (HCV) infection often persists in association with chronic hepatitis. Different factors have been proposed to determine the clinical outcome of HCV infection. The aim of this study was to examine three different factors of HCV infection among injecting drug users. Nineteen untreated HCV seroconverters were tested longitudinally for the presence of HCV RNA by reverse transcriptase (RT) PCR, and results were quantified by the branched-DNA (bDNA) assay. HCV genotypes were determined with the first sample taken after HCV seroconversion. To assess the natural course of infection, serum alanine aminotransferase (ALT) levels were measured at three stages in every individual. The concordance between bDNA and RT-PCR was 98.9%. Three distinct patterns were found, according to the HCV RNA load after seroconversion during a mean follow-up period of 5 years (range, 1 to 8 years). HCV genotype 1a was predominant (52.6%). There was a significant increase in serum ALT levels (mean 55.5 U/liter) in the early phase of HCV infection, compared with basal serum ALT levels before HCV seroconversion and at the end of the follow-up period. Three distinct HCV RNA load profiles were found, without apparent relationship to genotype and serum ALT levels in the first 5 years of HCV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9542901      PMCID: PMC104653          DOI: 10.1128/JCM.36.4.872-877.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam.

Authors:  J A van den Hoek; H J van Haastrecht; J Goudsmit; F de Wolf; R A Coutinho
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

2.  Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease.

Authors:  G Dusheiko; H Schmilovitz-Weiss; D Brown; F McOmish; P L Yap; S Sherlock; N McIntyre; P Simmonds
Journal:  Hepatology       Date:  1994-01       Impact factor: 17.425

3.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.

Authors:  L Stuyver; R Rossau; A Wyseur; M Duhamel; B Vanderborght; H Van Heuverswyn; G Maertens
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

4.  Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

Authors:  P Simmonds; F McOmish; P L Yap; S W Chan; C K Lin; G Dusheiko; A A Saeed; E C Holmes
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

5.  A longitudinal analysis of hepatitis C virus replication following liver transplantation.

Authors:  E J Gane; N V Naoumov; K P Qian; M U Mondelli; G Maertens; B C Portmann; J Y Lau; R Williams
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

6.  HCV-associated liver cancer without cirrhosis.

Authors:  M S De Mitri; K Poussin; P Baccarini; P Pontisso; A D'Errico; N Simon; W Grigioni; A Alberti; M Beaugrand; E Pisi
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

Review 7.  Correlates of hepatitis C virus infections among injection drug users.

Authors:  D L Thomas; D Vlahov; L Solomon; S Cohn; E Taylor; R Garfein; K E Nelson
Journal:  Medicine (Baltimore)       Date:  1995-07       Impact factor: 1.889

8.  Genotypes and virus load in patients with hepatitis C infection.

Authors:  H Hofmann
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

9.  Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA.

Authors:  H J Alter; R Sanchez-Pescador; M S Urdea; J C Wilber; R J Lagier; A M Di Bisceglie; J W Shih; P D Neuwald
Journal:  J Viral Hepat       Date:  1995       Impact factor: 3.728

Review 10.  Epidemiology of hepatitis C virus infection.

Authors:  R Esteban
Journal:  J Hepatol       Date:  1993       Impact factor: 25.083

View more
  12 in total

1.  [Postexposure prevention after occupational exposure to HBV, HCV and HIV].

Authors:  U Sarrazin; R Brodt; C Sarrazin; S Zeuzem
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

2.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

3.  Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies.

Authors:  M Beld; M Penning; M van Putten; A van den Hoek; V Lukashov; M McMorrow; J Goudsmit
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.

Authors:  Lin Liu; Brian E Fisher; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

5.  Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.

Authors:  Guang Y Li; Yun Zhou; Ruo S Ying; Lei Shi; Yong Q Cheng; Jun P Ren; Jeddidiah W D Griffin; Zhan S Jia; Chuan F Li; Jonathan P Moorman; Zhi Q Yao
Journal:  Hepatology       Date:  2015-02-04       Impact factor: 17.425

6.  Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment.

Authors:  Haldun Selcuk; Mehmet Kanbay; Murat Korkmaz; Gurden Gur; Ali Akcay; Hande Arslan; Nurhan Ozdemir; Ugur Yilmaz; Sedat Boyacioglu
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

7.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

8.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

9.  Clinical significance of activity of ALT enzyme in patients with hepatitis C virus.

Authors:  Onder Akkaya; Murat Kiyici; Yusuf Yilmaz; Engin Ulukaya; Omer Yerci
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

10.  Circulating viral core and E1 antigen levels as supplemental markers for HCV chronic hepatitis.

Authors:  Mostafa K El Awady; Yasmine S El Abd; Hussein A Shoeb; Ashraf A Tabll; Alaa El Din M S Hosny; Reem M El Shenawy; Khaled Atef; Noha G Bader El Din; Mahmoud M Bahgat
Journal:  Virol J       Date:  2006-09-01       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.